Atreca Past Earnings Performance

Past criteria checks 0/6

Atreca's earnings have been declining at an average annual rate of -14.6%, while the Biotechs industry saw earnings growing at 17.7% annually.

Key information

-14.6%

Earnings growth rate

51.1%

EPS growth rate

Biotechs Industry Growth-14.6%
Revenue growth raten/a
Return on equity-908.6%
Net Marginn/a
Last Earnings Update30 Sep 2023

Recent past performance updates

No updates

Recent updates

Revenue & Expenses Breakdown
Beta

How Atreca makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

MUN:0C1 Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 230-983645
30 Jun 230-853851
31 Mar 230-933958
31 Dec 220-973962
30 Sep 220-1054068
30 Jun 220-1104170
31 Mar 220-1084367
31 Dec 210-1094367
30 Sep 210-1034261
30 Jun 210-984259
31 Mar 210-923855
31 Dec 200-863752
30 Sep 200-833750
30 Jun 200-763348
31 Mar 200-742950
31 Dec 190-672449
30 Sep 190-591748
30 Jun 190-531343
31 Mar 190-441135
31 Dec 180-38931

Quality Earnings: 0C1 is currently unprofitable.

Growing Profit Margin: 0C1 is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 0C1 is unprofitable, and losses have increased over the past 5 years at a rate of 14.6% per year.

Accelerating Growth: Unable to compare 0C1's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 0C1 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14.4%).


Return on Equity

High ROE: 0C1 has a negative Return on Equity (-908.6%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.